In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.
It hasn't been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.
Eli Lilly (LLY) reachead $773.84 at the closing of the latest trading day, reflecting a -1.19% change compared to its last close.
Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to consumer stock Walmart completing such operations. Companies often launch this move after a long period of gains as a way to make their stock price more accessible to a wide range of investors.
If you're looking for top stocks, there's no need to reinvent the wheel. The Securities and Exchange Commission makes it a breeze to follow the world's greatest investors.
If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a lot of headache down the road is a necessity. In order to do so, it's important to find reliable businesses that are also on a growth trajectory.
It seems like just yesterday that vaccines used to combat the COVID-19 pandemic were all anyone in the medical world could talk about. Companies such as Pfizer, Moderna, and Johnson & Johnson captured myriad headlines as each of these businesses played an integral role in the development of vaccines used to treat COVID-19.
Eli Lilly (LLY -0.08%) is generating billions in cash flow growth due to product innovation.
Missed out on giant S&P 500 winners this year like Nvidia and Eli Lilly? Don't worry: Analysts think you'll get another shot in 2025.